Objective: In young children with asthmatic symptoms diagnostic difficulties lead to use of trials of asthma medication as a diagnostic tool. Our aim is to quantify the persistent use of asthma medication, initiated in the first year of life and identify determinants of this persistent use. Patients and methods: We identified 165 children within the PIAMA (Prevention and Incidence of Asthma and Mite Allergy) birth cohort who used asthma medication before the age of one. Persistent use was investigated during three years after the first prescription. A Cox regression analysis was performed to identify factors associated with persistent use. Results: A total of 58.8% of children continued using asthma medication after the first prescription and 10.3% continued during three years. Children with doctor-diagnosed asthma (Hazard ratio of discontinuation (HR) Z 0.64, 95% CI: 0.45e0.91) or prescribed inhaled corticosteroids in the first year of life (HR of discontinuation Z 0.59, 95% CI: 0.40e0.86) were 1.6e1.7 times more likely to continue using asthma medication. Conclusions: Persistence of asthma medication, prescribed in the first year of life is very low and is positively associated with doctor-diagnosed asthma and use of inhaled corticosteroids. Characterizing persistent users of asthma medication is important to understand prescribing of asthma medication in this age group. ª
KEYWORDS
Adherence; Asthma; Asthma medication; Cohort study; Pharmacoepidemiology; Preschool children Summary Objective: In young children with asthmatic symptoms diagnostic difficulties lead to use of trials of asthma medication as a diagnostic tool. Our aim is to quantify the persistent use of asthma medication, initiated in the first year of life and identify determinants of this persistent use. Patients and methods: We identified 165 children within the PIAMA (Prevention and Incidence of Asthma and Mite Allergy) birth cohort who used asthma medication before the age of one. Persistent use was investigated during three years after the first prescription. A Cox regression analysis was performed to identify factors associated with persistent use. Results: A total of 58.8% of children continued using asthma medication after the first prescription and 10.3% continued during three years. Children with doctor-diagnosed asthma (Hazard
Introduction
When a preschool child with symptoms suggestive of asthma presents at the physician's office, a diagnosis of asthma cannot be made with confidence. 1e4 It is well known that wheezing at a young age may not only be due to asthma but also to other, more transient, respiratory conditions. 2e6 Only a minority of wheezing children will develop persistent symptoms and will, therefore, be diagnosed as having asthma. 7e10 However, despite this diagnostic uncertainty, asthma medication is often prescribed to wheezing infants. Moreover, the response to asthma medication itself is widely used as a diagnostic tool to strengthen or reject the possible diagnosis of asthma. 3, 5, 11, 12 The GINA guidelines state that 'a trial of asthma medication is probably the most confident way to make a diagnosis on asthma in children'. 11 The rationale behind the trial treatment is that young children with wheezing but no underlying asthmatic disease are expected not to respond to treatment and will, therefore, discontinue treatment after evaluation of the effect. It is not known how often infants initiating such trial treatment benefit from the asthma medication and, therefore, continue medication use. 13 Notwithstanding the fact that asthmatic symptoms over time influence persistence of medication use, some patient characteristics, already known at start of asthma medication therapy, might be predictive of persistent asthma medication use in preschool children. If so, this could aid the decision whether or not to start a trial of asthma medication in a preschool child. The objective of this study is to quantify persistence of use of asthma medication in preschool children and identify possible determinants of persistence of use, which can be assessed at start of therapy.
Methods

Study design and study population
For this study we identified 165 children from the PIAMA (Prevention and Incidence of Asthma and Mite Allergy) study, who received asthma medication before the age of one.
The PIAMA study is a prospective birth cohort study among 4146 children. The design of the PIAMA study has been described in detail elsewhere. 14 In short, the participating children are born between July 1996 and October 1997. They were recruited from the general population through prenatal healthcare clinics in three different regions of the Netherlands. Data on respiratory and allergic symptoms, potential risk factors for asthma and allergy and demographic factors were collected by postal questionnaires. Parents were sent a questionnaire during the last trimester of pregnancy, at the child's age of three months and annually thereafter. Longitudinal data on medication use have been collected at age four through prescription data from community pharmacy records. In the Netherlands, pharmacy records are virtually complete with regard to drugs dispensed to patients. 15 Asthma medication and persistence of use Medical drug prescriptions were registered according to the Anatomical Therapeutic Chemical (ATC) Classification system. 16 All medicines with ATC code R03 were considered to be asthma medication: inhaled short acting b2-agonists (SABA), oral short acting b2-agonists, inhaled long acting b2-agonists (LABA), inhaled corticosteroids (ICS), inhaled cromones, anticholinergics and montelukast. Oral corticosteroids (H02AB) were not classified as primary asthma treatment. Persistence of use of asthma medication was investigated during a time-window of three years, using discontinuation rates. 17 The index date was defined as the date of the first prescription for asthma medication. Discontinuation of treatment was defined as the occurrence of a treatment gap of more than 365 days between one dispensing of asthma medication and a subsequent dispensing during the study time-window. Time to discontinuation was calculated as the number of days from the index date to the date of the last dispensing before the gap of more than 365 days þ a pre-specified time period of 90 days (which is the maximum duration of a single prescription in the Netherlands).
A wide treatment gap of 365 days is chosen because we want to quantify the amount of children receiving an initial prescription for asthma medication without needing asthma medication regularly over the next couple of years and compare these children with the ones who might still have intermittent or seasonal complaints but do return to use of asthma medication at least once every year. If the aim had been to determine continuing availability of asthma medication the allowed treatment gap would have been much smaller.
Statistical analysis
Persistence of use was examined using survival analysis, the endpoint being discontinuation of asthma medication. The overall persistence of use was determined using Kaplane Meier analyses. Univariate and multivariate Cox regression models were used to calculate unadjusted and adjusted hazard ratios and 95% confidence intervals (CI) for discontinuation of asthma medication use. The hazard ratio is the effect of a variable on the hazard or risk of an event. In our study the hazard ratio is the ratio of the rates at which children are discontinuing asthma medication in the two compared groups. In terms of interpretation, a hazard ratio of 0.5 for boys would mean that at any point in time half as many boys are discontinuing asthma medication proportionally compared to girls. One has to keep in mind that a variable with a low hazard ratio gives proportional a low likelihood of discontinuation; such a variable is, therefore, a strong predictor of persistence of treatment.
The following possible determinants of continuation of medication use were investigated, representing patient characteristics (gender, educational level of the parents), severity of symptoms (doctor-diagnosed asthma, prescribing of inhaled corticosteroids, antibiotic use), familial predisposition (allergic status of family members, eczema of the child, use of other allergy medication) and environmental influences (smoke exposure, pet exposure, day care). Because doctor-diagnosed asthma and prescribing of inhaled corticosteroids are expected to be related, an interaction term is added for these two variables. Statistical analyses were performed using SAS, version 9.1 (SAS Institute, Cary, NC).
Results
General characteristics of the study population of 165 children who started using asthma medication in their first year of life are shown in Table 1 . Male gender was predominant, with 69.7% boys in our study population. More than half (56%) of the study population had at least one parent with reported atopy (not shown in Table 1 ) and in 13% both parents were atopic. The most commonly used asthma medications were b2-agonists, prescribed to more than 80% of the study population and use of inhaled corticosteroids was seen in 40%. Almost 70% of the study population reported wheezing in the first year of life of which 30% also reported cough. Cough without wheeze was reported by 11% of the study population. The majority (57.6%) did not have parental-reported doctor-diagnosed asthma in the year asthma medication use was initiated.
Overall persistence of asthma medication use was low, falling below 15% after three years of follow-up (Fig. 1) . Since 41.2% of the study population received a single prescription for asthma medication, a steep fall in persistence can be observed after approximately three months of treatment. After these three months, a steady decline in persistence was seen, becoming less steep around 16 months of follow-up and reaching the level of 10.3% at the end of follow-up.
Results from the univariate Cox regression analyses are shown in Table 2 . Since the hazard ratios are for discontinuation of asthma medication, hazard ratios below 1.0 imply a higher persistence of asthma medication use. Most characteristics, including an allergic father, the use of antibiotics, eczema and pet exposure were not related to continuing use of asthma medication. Doctor-diagnosed asthma, prescribed inhaled corticosteroids and the allergic status of the mother were significantly associated with persistent use of asthma medication. After adjusting for the other significant variables and gender (see Table 3 ) only doctor-diagnosed asthma and use of inhaled corticosteroids remain significantly associated. Children with doctor-diagnosed asthma within the 1st year of life were 1.6 j Due to our selection criteria the use of asthma medication within the study population is 100%.
k Nasal antiallergics, systemic antihistamines, topical corticosteroids and antiallergic eye preparations. times more likely (hazard ratio of discontinuation Z 0.64) to continue asthma medication than children without such a diagnosis. The strongest determinant of persistence of use was a prescription for inhaled corticosteroids in the first year of life, with a highly significant hazard ratio of discontinuation of 0.59, rendering children using inhaled corticosteroids almost two times more likely to continue treatment than children not using these drugs. No interaction was found between the variables doctor-diagnosed asthma and inhaled corticosteroid use.
Repeating the multivariate Cox regression, including three dummy variables for the possible combinations of the variables doctor-diagnosed asthma and inhaled corticosteroid use, rendered a significant adjusted hazard ratio of discontinuation of 0.34 (95% CI: 0.25e0.63) for the group of children with both a diagnosis of asthma and use of inhaled corticosteroids. The difference in persistence between children with both doctor-diagnosed asthma and a prescription for inhaled corticosteroids and children without both, is visualized by a KaplaneMeier curve in Fig. 2 . The main difference in persistence between the groups was due to a difference in discontinuation after the first prescription. After this steep fall, the declining trend runs parallel between the compared groups.
Discussion
The study described here shows that 58.8% of children initiating asthma treatment before the age of one, continue medication use after the first prescription and only 10.3% is persistent after three years of follow-up. Children with doctor-diagnosed asthma and users of inhaled corticosteroids in the first year of life were 1.6e1.7 times more likely to continue using asthma medication. When both diagnosed with asthma and receiving inhaled corticosteroids, children were three times more likely to continue until the age of 3. No other measures were significantly associated with persistence of asthma medication use.
Our results show that most of the time a trial of asthma medication in very young children does not lead 
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Persistence of asthma medication use, % Figure 1 Persistence of asthma medication use within the study population: children receiving asthma medication in the 1st year of life. 
Persistence of asthma medication use, % Figure 2 Difference in persistence between children with both an asthma diagnosis and a prescription for inhaled corticosteroids (ICS) and children without both diagnosis and ICS in the first year of life.
to regular asthma medication use. Children who do become persistent asthma medication users could not be identified by objective measures that can be determined at start of therapy. Only the 'physician-decided' measures, doctor-diagnosed asthma and prescribing of inhaled corticosteroids are associated with persistent asthma medication use. The low persistence found in our study is consistent with the findings from previous studies that no valid criteria exist to prospectively identify children who will develop asthma within a group of wheezing children.
1,2,18e20 Moreover, a great proportion of those who wheezed in their first years of life did so for other reasons than asthma. 2e6 However, other studies did find certain factors to be associated with persistent wheeze and asthma later in life, including early allergic sensitization, 1, 9, 18, 21, 22 atopic disease (such as rhinitis, eczema), eosinophilia, 19, 22, 23 female sex, 21 tobacco smoke exposure, 21, 22 a family history of asthma, 1,9,19,22e25 early and/or severe wheezing. 18, 19, 25 Other characteristics, including pet or farm animal exposure, 18 day care attendance or having older siblings 18, 26 and house-dust endotoxine 18 might reduce the risk of asthma. This association is not reflected in an association with persistent asthma medication use. Our results show that demographic characteristics, familial predisposition and environmental influences were not significantly associated with persistence of asthma medication use.
In contrast, we found that doctor-diagnosed asthma and prescribing of inhaled corticosteroids were significantly associated with persistence of asthma medication use. As both these measures and the outcome, persistence of asthma medication use, are not objective measures but physician-based, care should be taken in interpreting these results. It is not unlikely that physicians are more inclined to continue medication use after diagnosing a child with asthma or prescribing inhaled corticosteroids. Therefore, it is important that physicians check the necessity of continuing medication on a regular basis. In addition, restricting treatment to the group of children with doctordiagnosed asthma and use of inhaled corticosteroids does not necessarily lead to better targeting of asthma medication, since a diagnosis of asthma is very difficult to make before the age of 5 and, if given, should be considered a working diagnosis. 11, 27, 28 However, the low percentage of persistence in our study and the finding that one-third of the children in our study population does not report wheezing in the year that asthma medication is initiated raises the question whether overtreatment occurs, as has been reported in previous studies. 1, 2, 13, 23, 29, 30 Especially since recent evidence suggests that early inhaled corticosteroid treatment has no effect on the natural history of asthma or wheeze later in childhood and that the beneficial effect during episodes of wheezing in preschool children is small to none existent. 20, 31, 32 Another study found no relation between responses to inhaled bronchodilators in infancy and asthma later in life, concluding that the presence or absence of a response to bronchodilators in early life cannot be used as a predictor of asthma. 33 The current study has some limitations. First, we only have information on medication use for the first four years of life, hence the maximum follow-up of three years after start of asthma therapy. We do realize that the diagnostic and treatment problems do not disappear at the age of 4. However, since already very few children remain persistent user after these three years we do not feel that the insight into persistent asthma medication use in this population would be much greater if we were able to add more years of follow-up. Second, in this study we cannot determine whether the persistence or discontinuation of medication is a just action. About one-third of all children discontinuing medication reported asthmatic symptoms in the year after their medication was discontinued (data not shown). This could imply undertreatment, especially since a quarter of non-persistent children resumes medication use in year 4. Third, parental-reported doctor-diagnosed asthma might not be the true reflection of asthmatics. This has been shown to differ substantially from a diagnosis of asthma derived from the GPs clinical records in the sense that selfreported asthma renders many more 'asthmatics' than do the GP's records. 34 In conclusion, we show that a treatment trial in most cases does not lead to regular use of asthma medication. Only 58.8% of children continue medication use after the initial prescription. With a three-year persistence of only 10.3% and the conflicting evidence on the benefit and diagnostic value of not only trials of inhaled corticosteroids, 20, 31, 32, 35, 36 but also b2-agonists 37 and anticholinergics 38 in children suffering from (transient) wheeze, there might be room for improvement in prescribing practice. It is important to identify which children should or should not be receiving asthma medication. However, our data showed that no objective measures, including a family history of asthma, eczema and smoke exposure, are associated with persistence of asthma medication use. These findings stress the need for objective tools to diagnose asthma at a young age. 
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